How global dealmaking in 2026 will reshape biopharma recruitment

We are seeing a more positive dealmaking landscape which we believe will reshape biopharma recruitment as we head into the new year.

After an uncertain start to 2025 marked by macroeconomic and policy headwinds (including tariff threats and looming drug-pricing reforms) the dealmaking environment has steadily gained a momentum which looks to continue in 2026. With valuations stabilising and strategies realigned, the industry appears ready to embrace a new chapter of mergers, acquisitions and strategic partnerships.

In the early months of 2025, biopharma dealmakers navigated an unpredictable landscape. Government policy and regulatory scrutiny, most notably from the Federal Trade Commission in the United States, cast a degree of uncertainty over some high-profile transactions. Yet as the year progressed, we saw companies and investors began to adjust their expectations, leading to more predictable valuations and a renewed willingness to commit to larger, lower-risk acquisitions. This correction in sentiment has set the stage for continued deal activity into 2026 and beyond.

One of the most striking trends from 2025 was the rebound in biopharma deal value. Deal data from the first half of the year showed biopharma deal value surpassing $138 billion, significantly outpacing the first half of 2024 and exceeding full-year totals from several recent years. June 2025 alone saw more than $35 billion in deal value, marking the strongest month of the year so far. (BioWorld) This surge reflects not just the recovery of dealmaker confidence, but also the strategic urgency felt within many organisations as they seek to address looming revenue losses caused by patent expirations.

We see the so-called “patent cliff” is increasingly shaping strategic behaviour among both biotech innovators and large pharmaceutical companies. With hundreds of billions of dollars in revenue at risk between now and 2030, we are finding companies are under significant pressure to diversify their pipelines through acquisitions, licensing agreements and partnerships. This dynamic is expected to be a key driver of dealmaking activity in 2026 as firms pursue assets that can provide immediate or near-term revenue potential.

Delving further, it seems that industry experts also anticipate that the sheer financial firepower held by major biopharma players will fuel sustained activity next year. Leading companies hold enormous capital reserves which give them flexibility to pursue strategic acquisitions or high-value collaborations. That financial strength, combined with a competitive imperative to replenish or expand pipelines, means that dealmakers are likely to act with renewed urgency in 2026. (Genetic Engineering & Biotechnology News)

Beyond traditional mergers and acquisitions, licensing deals and co-development partnerships are said to play an increasingly prominent role. As the industry evolves, firms are placing greater emphasis on collaboration over consolidation, particularly in areas such as oncology, rare disease and biologics, where specialised expertise and shared risk models can provide strategic advantage without requiring full buyouts. In many cases, it seems that these arrangements offer faster access to breakthrough science while preserving capital for broader portfolio investment.

Geography is another variable gaining traction in the dealmaking discourse. China, in particular, looks to be emerging as a significant force in global biopharma innovation. Increased licensing activity, especially in oncology, and growing high-quality data from China-based developers have positioned the region as a compelling source of deal opportunities. For multinational companies seeking new avenues for growth, Asia-Pacific markets are attracting attention not merely for manufacturing or commercialization advantages, but for upstream scientific innovation as well. (Fierce Pharma)

Of course, Artificial intelligence (AI) is another factor transforming deal dynamics. Beyond its disruptive impact on drug discovery and development workflows, AI is increasingly being recognised as a strategic asset in its own right. Buyers are now expected to ascribe discrete value to AI-enabled capabilities – especially those that demonstrably accelerate timelines, reduce risk or enhance regulatory readiness. As a result, it appears that companies with strong, validated AI platforms could command premium valuations in the transaction market, while those without such capabilities may face discounts or need to enter partnerships to stay competitive.

While the broader outlook for 2026 is overwhelmingly positive, it does seem that a degree of caution remains. Regulatory hurdles, ongoing global economic uncertainty and shifting political priorities can all influence the pace and scope of dealmaking activity. Nevertheless, analysts and industry observers are sharing a broadly optimistic view that the industry is entering a more structured and confident phase of strategic transactions. Many we speak to believe that 2026 could see not only an acceleration in overall deal volume, but also an increase in the number of transactions valued above $1 billion.

In conclusion, it seems that the biopharma dealmaking landscape for 2026 is being shaped by a confluence of strategic forces: stabilising valuations, patent-driven imperatives, abundant acquisition capital, the rise of China in innovation, and the growing influence of AI as a value generator. Together, these trends suggest a year in which companies will pursue both traditional M&A and innovative collaborative models with renewed confidence and purpose. For our clients across the life sciences ecosystem, understanding and anticipating these dynamics will be crucial to navigating the opportunities – and the challenges – that lie ahead.

What impact will the 2026 dealmaking landscape have on biopharma recruitment?

I believe that the resurgence of dealmaking heading into 2026 will have direct and meaningful implications for biopharma recruitment across life sciences, shaping not only who companies hire, but when, how and why. As M&A activity, licensing deals and strategic partnerships accelerate, talent strategy will increasingly be viewed as a core enabler of value rather than a downstream operational function.

First, deal activity almost always drives short-term spikes in hiring, particularly around integration, delivery and commercial readiness. As companies acquire late-stage assets or bolt-on platforms to address patent-cliff exposure, there will be heightened demand for professionals who can move quickly from due diligence into execution. This includes regulatory affairs specialists, clinical development leaders, medical affairs professionals and market access experts who can accelerate approvals and prepare products for launch. In many cases, these hires will be time-critical, favouring candidates with prior launch or post-merger integration experience.

Second, the increasing preference for licensing deals and co-development partnerships will shift hiring patterns away from pure headcount expansion toward more specialised, capability-driven recruitment. Rather than building large internal teams, companies will seek highly experienced individuals who can operate across partner ecosystems, manage external relationships and oversee complex governance structures. Alliance management, programme leadership and scientific project management roles are therefore likely to see sustained growth, particularly among mid-to-senior level candidates with cross-functional credibility.

The “patent cliff” will remain as one of the strongest underlying recruitment drivers. As blockbuster revenues come under pressure, we are seeing clients doubling down on pipeline diversification, which in turn fuels hiring in R&D, translational science and early clinical development. This will disproportionately benefit candidates with experience in high-growth therapeutic areas such as oncology, rare disease, cell and gene therapy and biologics. Competition for this talent is already intense, and dealmaking activity will only increase pressure on an already constrained talent pool.

Another notable impact we will see is likely to be on commercial and medical leadership hiring. Acquisitions of late-stage or marketed assets often trigger demand for medical directors, field medical leaders, brand leads and launch excellence specialists earlier than would typically be the case in organic pipeline development. As deal timelines compress, companies will increasingly recruit these roles in parallel with clinical and regulatory planning, rather than sequentially. This front-loaded hiring approach is likely to become more common in 2026.

AI-driven innovation and data-enabled platforms are now playing a more prominent role in deal valuations which will also reshape recruitment priorities. Organisations acquiring or partnering with AI-enabled tech will need talent capable of bridging science, data and regulation. This will drive demand for hybrid profiles such as computational biologists, clinical data scientists, AI-literate medical writers and regulatory professionals who understand algorithmic evidence generation. These profiles are scarce, highly mobile and likely to command premium compensation.

From a workforce-planning perspective, increased deal activity typically creates a two-speed hiring market. On one hand, acquisitive companies will accelerate recruitment in strategic growth areas. On the other, overlapping functions (particularly in corporate services, HR and some operational roles) may face consolidation or restructuring post-deal. This dynamic often results in short-term talent availability at senior levels, followed by rapid reabsorption into the market as new opportunities emerge.

Geographic considerations will also become more important. As China and other Asia-Pacific markets continue to influence global deal flow, pharma companies may increasingly recruit talent with international regulatory experience, cross-border clinical expertise and global launch exposure. This will benefit candidates who have operated across multiple regulatory jurisdictions or within global matrix environments.

Finally, the renewed confidence in dealmaking is likely to have a knock-on effect on candidate behaviour. As market sentiment improves, passive candidates are more likely to engage in conversations, increasing movement at the top end of the market. However, expectations around flexibility, purpose, leadership quality and stability will remain high. Candidates should (and will) be acutely aware of integration risk and cultural disruption following M&A, making employer messaging and transparency critical to successful hiring – something we advocate highly.

In summary, we are advising clients that an active biopharma dealmaking environment in 2026 will intensify competition for specialist talent, accelerate hiring timelines and reinforce the importance of proactive workforce planning. Those organisations that succeed will be those that align talent strategy with transaction strategy early -anticipating skills gaps, securing critical expertise ahead of need and using recruitment as a lever to maximise deal value rather than reacting once transactions are complete.

Are you looking for support with talent acquisition in 2026? 

Established in 2006 by ex-industry professionals, Carrot has become one of the most highly regarded and trusted recruitment partners within the Pharma, Biotech, and Med-Tech sectors, spanning North America and Europe. Our business is structured to support clients across the full product lifecycle, from development to commercialisation and everything in between, with dedicated recruitment teams working exclusively across 14 separate functional areas.

Register a vacancy Read our case studies

Looking for your next role within Pharma, Biotech or Life Sciences?

Submit your CV

Debbie Anderson

Founding Director